A very short duration that still showed an extremely high safety profile at high doses. We just need to repeat this and judging by the retts community excitement for trof, we are already home and hosed.
I was reading a q and a and one of the questions was asking if patients can still take trof if it fails P3 but they were partaking in the trial. Retts community need this.
- Forums
- ASX - By Stock
- NEU
- FDA exercises rare disease flexibility
FDA exercises rare disease flexibility, page-6
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B |
Open | High | Low | Value | Volume |
$14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | $16.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$16.57 | 1717 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 16.520 |
2 | 400 | 16.480 |
1 | 300 | 16.470 |
2 | 1367 | 16.440 |
2 | 5242 | 16.400 |
Price($) | Vol. | No. |
---|---|---|
16.570 | 1717 | 1 |
16.590 | 1367 | 2 |
16.600 | 4715 | 3 |
16.620 | 2306 | 2 |
16.650 | 2000 | 1 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online